Evidence map›Paper›PMID 27837416›Full record

ArticleInternational urology and nephrology2017

A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.

Wei Lv, Hongxiang Shang, Xinqi Pei, Yule Chen, Hongjun Xie, Dalin He, Xinyang Wang, Lei Li

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei LvDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710061, China.
Hongxiang ShangDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710061, China.
Xinqi PeiDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710061, China.
Yule ChenDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710061, China.
Hongjun XieDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710061, China.
Dalin HeDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710061, China.
Xinyang WangDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710061, China.
Lei LiDepartment of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710061, China. lilydr@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo distinguish potential biomarkers and build a useful model to predict the time required to progress to castration-resistant prostate cancer (CRPC) in patients with prostate cancer who have been treated with androgen deprivation therapy (ADT).

methodsWe considered 168 patients who received ADT as the initial therapy. Complete clinical data including age, tumor stage, Gleason score, prostate-specific antigen (PSA), complete blood count and liver function tests were analyzed. Cox proportional hazards regression models were used to estimate their effects on the time required to progress to CRPC, and a simple risk stratification model to predict the time required to progress to CRPC was established.

resultsOne hundred and sixty-eight patients were evaluated. The median age was 72 years, and the mean time required to progress to CRPC was 15 months. Multivariable analysis indicated that PSA, alkaline phosphatase and albumin were independent predictors of ADT failure. A predictor model using these factors indicated significant differences in the time required to progress to CRPC between the three subgroups: low (score: 0), intermediate (score: 1-2) and high (score: 3-4).

conclusionThe predictor model included PSA, alkaline phosphatase and albumin as independent prognostic factors of the time required to progress to CRPC in patients who had received ADT.

Indexed as

Disease ProgressionProstatic Neoplasms, Castration-ResistantAgedAlkaline PhosphataseAndrogen AntagonistsAnilidesAntineoplastic Agents, HormonalGonadotropin-Releasing HormoneHumansMaleNitrilesOrchiectomyPredictive Value of TestsProportional Hazards ModelsProstate-Specific AntigenProstatic NeoplasmsAlkaline PhosphataseAndrogen AntagonistsAnilidesAntineoplastic Agents, HormonalbicalutamideGonadotropin-Releasing HormoneNitrilesProstate-Specific AntigenSerum AlbuminTosyl CompoundsAlbuminAlkaline phosphataseAndrogen deprivation therapyCastration-resistant prostate cancerProstate-specific antigen

Identifiers

PMID27837416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.